Search Result

Results for "

pain models

" in MedChemExpress (MCE) Product Catalog:

By Targets:	5-HT Receptor (1) Adenosine Receptor (2) Adenylate Cyclase (1) Aminopeptidase (1) Apoptosis (5) Bradykinin Receptor (1) Calcium Channel (2) Cannabinoid Receptor (7) COX (2) CXCR (1) Cytochrome P450 (1) FAAH (2) GlyT (2) Histamine Receptor (1) JAK (1) MAGL (3) Mas-related G-protein-coupled Receptor (MRGPR) (1) mGluR (2) nAChR (1) NO Synthase (1) Opioid Receptor (6) P2X Receptor (6) Prostaglandin Receptor (3) Sigma Receptor (5) Sodium Channel (9) Somatostatin Receptor (2) Toll-like Receptor (TLR) (1) TRP Channel (2)
By Research Areas:	Cancer (3) Cardiovascular Disease (2) Endocrinology (2) Inflammation/Immunology (25) Neurological Disease (48)

By Targets:

5-HT Receptor (1)

Adenosine Receptor (2)

Adenylate Cyclase (1)

Aminopeptidase (1)

Apoptosis (5)

Bradykinin Receptor (1)

Calcium Channel (2)

Cannabinoid Receptor (7)

COX (2)

CXCR (1)

Cytochrome P450 (1)

FAAH (2)

GlyT (2)

Histamine Receptor (1)

JAK (1)

MAGL (3)

Mas-related G-protein-coupled Receptor (MRGPR) (1)

mGluR (2)

nAChR (1)

NO Synthase (1)

Opioid Receptor (6)

P2X Receptor (6)

Prostaglandin Receptor (3)

Sigma Receptor (5)

Sodium Channel (9)

Somatostatin Receptor (2)

Toll-like Receptor (TLR) (1)

TRP Channel (2)

By Research Areas:

Cancer (3)

Cardiovascular Disease (2)

Endocrinology (2)

Inflammation/Immunology (25)

Neurological Disease (48)

Inhibitors & Agonists

Peptides

Natural
Products

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-106199

Adenosine A1 receptor activator T62 1 Publications Verification	Adenosine Receptor	Neurological Disease Inflammation/Immunology
Adenosine A1 receptor activator T62 is an allosteric enhancer of adenosine A1 receptor. Adenosine A1 receptor activator T62 produces antinociception in animal models of acute pain and also reduces hypersensitivity in models of inflammatory and nerve-injury pain .

HY-P5900

m3-Huwentoxin IV m3-HwTx-IV	Sodium Channel	Neurological Disease
m3-Huwentoxin IV (m3-HwTx-IV) is a potent Na_V inhibitor with IC₅₀s of 3.3, 6.8, 7.2, 8.4, 11.9 and 369 nM against hNa_V1.7, hNa_V1.6, hNa_V1.3, hNa_V1.1, hNa_V1.2 and hNa_V1.4, respectively in QPatch assay. m3-Huwentoxin IV dose-dependently suppresses spontaneous pain induced by the Na_V1.7 activator OD1 in a rodent pain model .

HY-163065

σ1 Receptor/μ Opioid receptor modulator 2	Opioid Receptor Sigma Receptor	Neurological Disease
σ1 Receptor/μ Opioid receptor modulator 2 (compound 4x) is a dual μOR agonist/σ1R antagonist, and displays picomolar μOR agonism activity (EC₅₀: 0.6 ± 0.2 nM) and good σ1R inhibitory activity (K_i: 363.7 ± 5.6 nM). σ1 Receptor/μ Opioid receptor modulator 2 exhibits robust analgesic effects in various pain models .

HY-107561

A-943931 hydrochloride	Others	Inflammation/Immunology
A-943931 (Compound 10) is a histamine H₄ receptor antagonists. A-943931 has improved pharmacotropic and in vivo efficacy in models of pain and inflammation. A-943931 can be used in vivo anti-inflammatory and anti-nociception research .

HY-155417

GPR34 receptor antagonist 3	Others	Neurological Disease
GPR34 receptor antagonist 3 (Compound 5e) is a class of GRP34 antagonists, IC₅₀ is 0.680 μM. GPR34 receptor antagonist 3 inhibited ERK1/2 phosphorylation induced by lysophosphatidylserine in a dose-dependent way without obvious cytotoxicity. GPR34 receptor antagonist 3 shows antisensory activity in mouse neuropathic pain model .

HY-111029

ALX-1393

GlyT Neurological Disease

ALX-1393, a selective GlyT2 inhibitor, has an antinociceptive effect on thermal, mechanical, and chemical stimulations in a rat acute pain model .

ALX-1393	GlyT	Neurological Disease
ALX-1393, a selective GlyT2 inhibitor, has an antinociceptive effect on thermal, mechanical, and chemical stimulations in a rat acute pain model .

HY-113608

VCP171	Adenosine Receptor	Neurological Disease
VCP171 is a potent adenosine A1 receptor (A1R) positive allosteric modulator (PAM). VCP171 is effective at decreasing excitatory synaptic currents in Lamina II of neuropathic pain model. VCP171 can be used for researching neuropathic pain .

HY-N3710

Dehydrocrenatidine Kumujian G; O-Methylpicrasidine I	JAK Apoptosis	Neurological Disease Cancer
Dehydrocrenatidine, a natural alkaloid, is a specific JAK inhibitor. Dehydrocrenatidine inhibits voltage-gated sodium channels and ameliorates mechanic allodia in a rat model of neuropathic pain .

HY-111029A

ALX-1393 TFA

GlyT Others

ALX-1393 TFA, a selective GlyT2 inhibitor, has an antinociceptive effect on thermal, mechanical, and chemical stimulations in a rat acute pain model .

ALX-1393 TFA	GlyT	Others
ALX-1393 TFA, a selective GlyT2 inhibitor, has an antinociceptive effect on thermal, mechanical, and chemical stimulations in a rat acute pain model .

HY-N2258

Poncirin 1 Publications Verification
Poncirin is isolated from Poncirus trifoliata with anti-inflammory activites. Poncirin significantly reduces mechanical hyperalgesia and allodynia in Complete Freund’s Adjuvant (CFA)-induced inflammatory pain models .

HY-118952

PF-06456384	Sodium Channel	Neurological Disease
PF-06456384 is a highly potent and selective Na_V1.7 inhibitor with an IC₅₀ of 0.01 nM. PF-06456384 has the potential for formalin pain model research .

HY-118952A

PF-06456384 trihydrochloride	Sodium Channel	Neurological Disease
PF-06456384 trihydrochloride is a highly potent and selective Na_V1.7 inhibitor with an IC₅₀ of 0.01 nM. PF-06456384 trihydrochloride has the potential for formalin pain model research .

HY-111258

GSK345931A	Prostaglandin Receptor	Neurological Disease Inflammation/Immunology
GSK345931A is an EP1 receptor antagonist. GSK345931A shows measurable CNS penetration in the mouse and rat and potent analgesic efficacy in acute and sub-chronic models of inflammatory pain .

HY-N5025

Bullatine A	P2X Receptor Apoptosis	Inflammation/Immunology Cancer
Bullatine A, a diterpenoid alkaloid of the genus Aconitum, possesses anti-rheumatic, anti-inflammatory and anti-nociceptive effects. Bullatine A is a potent P2X7 antagonist, inhibits ATP-induced cell death/apoptosis and P2X receptor-mediated inflammatory responses . Bullatine A attenuates pain hypersensitivity, regardless of the pain models employed .

HY-10635

ABT-102	TRP Channel	Inflammation/Immunology Cancer
ABT-102 is a potent and highly selective Vanilloid Receptor (TRPV1) receptor antagonist. ABT-102 potently and reversibly increases heat pain thresholds and reduced painfulness of suprathreshold oral/cutaneous heat. ABT-102 reduces nociceptive responses of animals in models of inflammatory, bone cancer, postoperative, and osteoarthritic pain .

HY-119033

MGL-IN-1	MAGL	Inflammation/Immunology
MGL-IN-1 is a potent and selective irreversible MGL (β-lactam-based monoacylglycerol lipase) inhibitor. MGL-IN-1 alleviates symptoms in a MS model in vivo and exhibits analgesic effects in an acute inflammatory pain model in vivo. MGL-IN-1 displays high membrane permeability and brain penetrant .

HY-P5802

ω-Conotoxin FVIA	Calcium Channel	Neurological Disease
ω-Conotoxin FVIA is an N-type Ca ²⁺channel (Ca_v2.2) inhibitor. ω-Conotoxin FVIA reduces mechanical and thermal pain abnormalities in a rat model of caudal nerve injury. ω-Conotoxin FVIA can be used in the study of highly effective pain relievers with low side effects .

HY-150270

NP-1815-PX	P2X Receptor	Neurological Disease Inflammation/Immunology
NP-1815-PX is a potent and selective P2X4R antagonist. NP-1815-PX has anti-inflammatory activity, and can relieve pain in chronic pain models. NP-1815-PX also inhibits guinea pig tracheal/bronchial smooth muscle (TSM and BSM) contractions .

HY-150270A

NP-1815-PX sodium	P2X Receptor	Neurological Disease Inflammation/Immunology
NP-1815-PX sodium is a potent and selective P2X4R antagonist. NP-1815-PX sodium has anti-inflammatory activity, and can relieve pain in chronic pain models. NP-1815-PX sodium also inhibits guinea pig tracheal/bronchial smooth muscle (TSM and BSM) contractions .

HY-P5874

Myr-TAT-CBD3	Calcium Channel	Inflammation/Immunology
Myr-TAT-CBD3 is CRMP2-CaV2.2 interaction inhibitor. Myr-tat-CBD3 can significantly attenuate carrageenan-induced thermal hypersensitivity and reverse thermal hypersensitivity induced in a rat model of postoperative pain. Myr-TAT-CBD3 can be used to study inflammation and postoperative pain .

HY-P1330

Purotoxin 1	P2X Receptor	Inflammation/Immunology
Purotoxin 1 is a P2X3 receptor inhibitor. Purotoxin 1 shows antinociceptive properties in animal models of inflammatory pain. Purotoxin 1 can be isolated from the venom of the wolf spider Geolycosa sp .

HY-15451

MDA 19 1 Publications Verification	Cannabinoid Receptor	Neurological Disease
MDA 19 is a potent and selective agonist of human cannabinoid receptor 2 (CB2), with a K_i of 43.3 nM. MDA 19 has antiallodynic effects in a rat model of neuropathic pain and does not affect rat locomotor activity .

HY-P5848

αO-Conotoxin GeXIVA	nAChR	Neurological Disease
αO-Conotoxin GeXIVA is a potent α9α10 nAChR antagonist with an IC₅₀ of 12 nM against rat α9α10. αO-Conotoxin GeXIVA shows analgesic in animal models of pain .

HY-149855

AB10	Sigma Receptor	Others
AB10 is a selective S1R antagonist. AB10 with K_i of 10, 165 nM for S1R and S2R, respectively. AB10 reverses the effect of Capsaicin (HY-10448) caused pain in model .

HY-P5907

Helianorphin-19	Opioid Receptor	Neurological Disease
Helianorphin-19 is a potent and selective κ-opioid receptor (KOR) activator with a K_i of 21 nM and an EC₅₀ of 45 nM. Helianorphin-19 exhibits strong KOR-specific peripheral analgesic activity in a mouse model of chronic visceral pain .

HY-131004

CB2R PAM	Cannabinoid Receptor	Neurological Disease
CB2R PAM is an orally active cannabinoid type-2 receptors (CB2Rs) positive allosteric modulator. CB2R PAM displays antinociceptive activity in vivo in an experimental mouse model of neuropathic pain .

HY-14886

Fasitibant chloride MEN16132 free base	Bradykinin Receptor	Cardiovascular Disease Neurological Disease
Fasitibant chloride (MEN16132 free base) is a potent and selective nonpeptide bradykinin B2 receptor (B2R) antagonist. Fasitibant chloride reduces joint pain and diminishes joint oedema in Carrageenan-induced arthritis rat model .

HY-110036A

GW405833 hydrochloride L768242 hydrochloride	Cannabinoid Receptor	Neurological Disease
GW405833 hydrochloride is a potent and selective cannabinoid-2 (CB2) receptor agonist (EC₅₀ = 0.65 nM; maximum inhibition = 44.6%). GW405833 hydrochloride produces potent antihyperalgesic effects in several rodent models of pain .

HY-103344

ZJ43	Aminopeptidase mGluR	Neurological Disease Inflammation/Immunology
ZJ43 is a potent NAAG peptidase inhibitor, with an IC₅₀ of 2.4 nM and a K_i of 0.8 nM. ZJ43 sufficiently activates group II mGluR and reduces some of the behavioral effects of PCP. ZJ43 shows an analgesic effect in neuropathic and inflammatory and pain models .

HY-142700

SSTR4 agonist 3	Somatostatin Receptor	Neurological Disease
SSTR4 agonist 3 is a potent agonist of SSTR4. SSTR4 is expressed at relatively high levels in the hippocampus and neocortex, memory and learning regions, and Alzheimer's disease pathology. SSTR4 agonists are potent in rodent models of pain associated with acute and chronic associated anti-peripheral nociceptive and anti-inflammatory activity. SSTR4 agonist 3 has the potential for the research of pain (extracted from patent WO2021233427A1, compound 14) .

HY-142701

SSTR4 agonist 4	Somatostatin Receptor	Neurological Disease
SSTR4 agonist 4 is a potent agonist of SSTR4. SSTR4 is expressed at relatively high levels in the hippocampus and neocortex, memory and learning regions, and Alzheimer's disease pathology. SSTR4 agonists are potent in rodent models of pain associated with acute and chronic associated anti-peripheral nociceptive and anti-inflammatory activity. SSTR4 agonist 4 has the potential for the research of pain (extracted from patent WO2021233428A1, compound 14) .

HY-133130

JNJ-42226314	MAGL	Neurological Disease
JNJ-42226314 is a competitive, highly selective and reversible non-covalent monoacylglycerol lipase (MAGL) inhibitor. JNJ-42226314 demonstrates dose-dependent enhancement of the major endocannabinoid 2-arachidonoylglycerol (2-AG) as well as efficacy in models of neuropathic and inflammatory pain .

HY-P1091

Hemopressin (human, mouse)	Cannabinoid Receptor	Neurological Disease
Hemopressin is a nonapeptide derived from the α1-chain of hemoglobin, is originally isolated from rat brain homogenates. Hemopressin is orally active, selective and inverse agonist of CB1 cannabinoid receptors. Hemopressin exerts antinociceptive action in inflammatory pain models .

HY-143880

MRGPRX1 agonist 4	Mas-related G-protein-coupled Receptor (MRGPR)	Neurological Disease
MRGPRX1 agonist 4 (compound 1t) is a potent and orally active Mas-related G protein-coupled receptor X1 (MRGPRX1) positive allosteric modulator with an EC₅₀ value of 0.1 μM. MRGPRX1 agonist 4 has good metabolic stability and oral bioavailability. MRGPRX1 agonist 4 can reduce behavioral heat hypersensitivity in a neuropathic pain model humanized MRGPRX1 mice. MRGPRX1 agonist 4 can be used for researching neuropathic pain .

HY-110199

TC-I 2014	TRP Channel	Neurological Disease
TC-I 2014 (compound 5) is a potent and orally active Benzimidazole-containing transient receptor potential melastatin 8 (TRPM8) antagonist, with IC₅₀ values of 0.8 nM, 3.0 nM and 4.4 nM for canine, human and rat channels respectively. TC-I 2014 exhibits antiallodynic properties in pain models .

HY-P1090

Hemopressin(rat)	Cannabinoid Receptor	Neurological Disease
Hemopressin(rat) is a nonapeptide derived from the α1-chain of hemoglobin, is originally isolated from rat brain homogenates. Hemopressin(rat) is orally active, selective and inverse agonist of CB1 cannabinoid receptors. Hemopressin(rat) exerts antinociceptive action in inflammatory pain models .

HY-P1091A

Hemopressin(human, mouse) TFA	Cannabinoid Receptor	Neurological Disease
Hemopressin TFA is a nonapeptide derived from the α1-chain of hemoglobin, is originally isolated from rat brain homogenates. Hemopressin TFA is orally active, selective and inverse agonist of CB1 cannabinoid receptors. Hemopressin TFA exerts antinociceptive action in inflammatory pain models .

HY-145830

AC1-IN-1	Adenylate Cyclase	Neurological Disease
AC1-IN-1 is a potent and selective Adenylyl cyclase type 1 (AC1) inhibitor with an IC₅₀ of 0.54 µM. AC1-IN-1 displays modest antiallodynic effects in a mouse model of inflammatory pain. AC1-IN-1 has CNS activity .

HY-P3223

Biphalin TFA	Opioid Receptor	Neurological Disease
Biphalin TFA, a BBB-penetrable opioid peptide analog, contains two active enkephalin pharmacophores. Biphalin TFA has high affinity for opioid receptors. Biphalin TFA shows analgesic effect in acute, neuropathic, and chronic animal pain models. Biphalin TFA is also an antiviral, antiproliferative, anti-inflammatory, and neuroprotective agent .

HY-P1090A

Hemopressin(rat) TFA	Cannabinoid Receptor	Neurological Disease
Hemopressin(rat) TFA is a nonapeptide derived from the α1-chain of hemoglobin, is originally isolated from rat brain homogenates. Hemopressin(rat) TFA is orally active, selective and inverse agonist of CB1 cannabinoid receptors. Hemopressin(rat) TFA exerts antinociceptive action in inflammatory pain models .

HY-131019

JF-NP-26	mGluR	Neurological Disease
JF-NP-26, an inactive photocaged derivative of raseglurant, is the first caged mGlu5 receptor negative allosteric modulator. Uncaging of JF-NP-26 is elicited with light pulses in the visible spectrum (405 nm). JF-NP-26 induces light-dependent analgesia in models of inflammatory and neuropathic pain in freely behaving animals .

HY-103461

FAAH-IN-6	FAAH	Neurological Disease
FAAH-IN-6 (compound 21d) is a potent, orally active and cross the blood-brain barrier fatty acid amide hydrolase (FAAH) inhibitor with IC₅₀s of 0.72, 0.28 nM for hFAAH, rFAAH, respectively. FAAH-IN-6 shows dose-dependent analgesic efficacy in animal models of both neuropathic and inflammatory pain .

HY-110099

(±)-NBI-74330	CXCR	Inflammation/Immunology
(±)-NBI-74330 is a potent and selective CXCR3 antagonist. (±)-NBI-74330 not only reduces tactile and thermal hypersensitivity but also enhances the analgesic properties of morphine. (±)-NBI-74330 can reduce microglial cell activation, increase astroglial cell activation, and downregulate the expression of some CXCR3 ligands in a rat neuropathic pain model .

HY-14485

Ro-51	P2X Receptor	Neurological Disease
Ro-51 is a potent and selective dual P2X₃/P2X_2/3 antagonist, with IC₅₀ of 2 nM and 5 nM for P2X₃ and P2X_2/3, respectively. Ro-51 can be used for the research for pain .

HY-10413

MK-2894 1 Publications Verification	Prostaglandin Receptor	Inflammation/Immunology Endocrinology
MK-2894 is a potent, selective, orally active and high affinity (K_i=0.56 nM) full antagonist against E prostanoid receptor 4 (EP4 receptor) (IC₅₀=2.5 nM). MK-2894 possesses potent anti-inflammatory activity in animal models of pain/inflammation and can be used for the research of arthritis .

HY-10414

MK-2894 sodium salt	Prostaglandin Receptor	Inflammation/Immunology Endocrinology
MK-2894 sodium salt is a potent, selective, orally active and high affinity (K_i=0.56 nM) full antagonist against E prostanoid receptor 4 (EP4 receptor) (IC₅₀=2.5 nM). MK-2894 sodium salt possesses potent anti-inflammatory activity in animal models of pain/inflammation and can be used for the research of arthritis .

HY-N6967

Levomenol (-)-α-Bisabolol	Apoptosis	Neurological Disease Inflammation/Immunology
Levomenol ((-)-α-Bisabolol), a monocyclic sesquiterpene alcohol, exerts antioxidant, anti-inflammatory, and anti-apoptotic activities. Levomenol also has neuroprotective effects and prevents neuronal damage and memory deficits through reduction of proinflammatory markers induced by permanent focal cerebral ischemia in mice. Levomenol attenuates nociceptive behaviour and central sensitisation in a rodent model of trigeminal neuropathic pain. Orally active .

HY-11079

A-803467 1 Publications Verification	Sodium Channel	Neurological Disease Inflammation/Immunology
A-803467 is a potent and selective tetrodotoxin-resistant Na_v1.8 sodium channel blocker (IC₅₀=8 nM). A-803467 has shown significant anti-nociception in neuropathic and inflammatory pain models. A-803467 enhances the chemosensitivity of conventional anticancer agents through interaction with the ATP-binding cassette subfamily G member 2 (ABCG2) transporter .

HY-13954

A 839977 1 Publications Verification	P2X Receptor	Neurological Disease Inflammation/Immunology
A 839977 is a P2X7 selective antagonist; it blocks BzATP-evoked calcium influx at recombinant human, rat and mouse P2X7 receptors (IC₅₀ values are 20 nM, 42 nM and 150 nM respectively) and reduces inflammatory and neuropathic pain in animal models; the antihyperalgesic effects of P2X7 receptor blockade are mediated by blocking the release of IL-1beta .

HY-18618

SB-612111	Opioid Receptor	Neurological Disease Inflammation/Immunology
SB-612111 is a novel and potent opiate receptor-like orphan receptor (ORL-1) antagonist with a high affinity for hORL-1 (K_i=0.33 nM). SB-612111 exhibits selectivity for μ-, κ- and δ-receptors with K_i values of 57.6 nM, 160.5 nM and 2109 nM, respecticely. SB-612111 effectively antagonizes the pronociceptive action of Nociceptin (HY-P0183) in an acute pain model .

Cat. No.	Product Name	Target	Research Area